Dr. Peter T. Silberstein, MD

Dr. Silberstein practices at CHI Health University Campus Emergency Department - Emergency Department - HOPD in Omaha, Nebraska.

Dr. Silberstein's NPI, 1952415317, was assigned on August 19, 2006. Dr. Silberstein graduated from State University of NY Upstate Medical University in 1979. Dr. Silberstein holds Nebraska license 22062.

Dr. Silberstein's primary practice is CHI Health University Campus Emergency Department - Emergency Department - HOPD, at 2412 Cuming St, Omaha, NE 68131.

Dr. Silberstein's primary practice is CHI Health University Campus Emergency Department - Emergency Department - HOPD in Omaha, Nebraska. Dr. Silberstein is also affiliated with CHI Health Creighton University Medical Center - Bergan Mercy. The medical group on file is CHI Health Clinic. Dmand AI also links Dr. Silberstein to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Silberstein practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Silberstein's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Silberstein is licensed in Nebraska.

CMS data shows 1,615 Medicare services from Dr. Silberstein across 13 procedure codes in 2024, for 531 Medicare patients. Medicare paid $117,553 for them.

CMS counts 531 Medicare patients who saw Dr. Silberstein in 2024. The largest group is 65 to 74, with 249 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 12% are also on Medicaid. Their average risk score is 1.86, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Silberstein's median patient age at 65, with 53% women.

In 2024, Dr. Silberstein wrote 1,208 Medicare Part D claims for 196 patients. 73% of them were for generic drugs. CMS names the drug for 1,039 of them, across 36 drugs with 11 or more claims each, at $2,970,335 in total drug cost. In 2023, CMS named 953 claims across 27 drugs.

Dr. Silberstein accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Silberstein as offering telehealth.

Dmand AI links 80 papers to Dr. Silberstein, published from 2010 to 2025. 2024 was the busiest year, with 14. The most frequent topics are Skin Neoplasms, Black or African American and Carcinoma, Squamous Cell. Dr. Silberstein has published most often in Cureus. Dr. Silberstein's most frequent co-authors are Gaurav Goyal, Vijaya Raj Bhatt, MD and Aabra Ahmed, MD.

CMS Open Payments shows 849 general payments to Dr. Silberstein from 52 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 57% of the total. Incyte Corporation paid the most, $84,488.

Dr. Silberstein graduated from State University of NY Upstate Medical University in 1979.